ORAMED PHARMACEUTICL | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (35)

View All

Latest Posts

About This Stock More About This Stock
Seven Biotech Names On The Upswing: 2016 Small-Cap Biotech Watchlist Update
Article By: The Life Sciences Report
Wednesday, March 9, 2016 5:47 PM EDT
Biotech stocks—and the stock market in general—took a dive at the beginning of 2016, headed down on macroeconomic factors such as financial instability in China.
In this article: SGYP, CRMD, ORMP, SRNE, ARRY, PTIE, AGEN, GALE, PPHM, EVOK, ADMA, AKBA, KPTI, VSTM, AST, RXDX, AGTC, WVE, FATE, FLKS, PIRS, ABEO
Read
The 2016 Small-Cap Biotech Watchlist Debuts At The Biotech Showcase
Article By: The Life Sciences Report
Wednesday, January 27, 2016 6:16 PM EDT
This may prove a challenging year for small-cap biotechs, but the five analysts who selected companies for inclusion on The Life Sciences Report's 2016 Small-Cap Biotech Watchlist believe these companies have a good producing value for investors.
In this article: AZN, NVO, SGYP, SNY, CRMD, ORMP, CMXHY, SRNE, ALNY, ARRY, INCY, IRWD, PTIE, REGN, VRTX, AGEN, GALE, GRFS, PPHM, EVOK, ADMA, AKBA, VSTM, AST, RXDX, AGTC, NK, WVE, FATE, FLKS
Read
Week In Review: 3SBio Uses M&A To Expand Portfolio Of Biosimilars
Article By: ChinaBio® Today
Saturday, December 5, 2015 11:58 AM EDT
3SBio of Shenyang expanded its biosimilar business by raising its stake in Shanghai CP Guojian Pharma to 54%. 3SBio, which acquired 7% of Guojian last year, paid $213 million for 47% of Guojian's outstanding shares.
In this article: ORMP, AMGN, BIIB, KANG
Read
Week In Review: WuXi's SynTheAll Subsidiary Raises $80 Million
Article By: ChinaBio® Today
Saturday, July 11, 2015 1:33 PM EDT
WuXi PharmaTech, a China-US CRO/CMO, announced its SynTheAll Pharma subsidiary, a small-molecule manufacturing company will raise $80 million through a private placement of 6% of its shares.
In this article: AZN, IRWD, MR, ORMP, WX
Read
Week In Review: WuXi PharmaTech To List Subsidiary On China's Third Board
Article By: ChinaBio® Today
Tuesday, December 9, 2014 5:45 PM EDT
China's largest CRO/CMO, has filed to list its chemical manufacturing subsidiary, SynTheAll Pharmaceutical Co. Ltd., on China's Third Board, a two-year old electronic OTC exchange. Shanghai Fosun Pharma will acquire a 65% sake in Suzhou Erye Pharma and more.
In this article: WX, ORMP, AEZS
Read
All Posts

Latest Tweets for $ORMP

No tweets yet!

PARTNER HEADLINES

$ORMP

Comments Status Updates
Here's My Top Value Stock To Buy Right Now
Mike Faragut • 11/1/2021 1:38:52 PM

$ORMP is has interesting value. They've just announced that they're starting Phase I trials for their oral covid vaccine. Keep an eye on it today,

1 to 1 of 1 comments